Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
PMV Pharmaceuticals announced updated interim Phase 2 clinical trial data for rezatapopt in ovarian cancer, showing a 46% overall response rate with a 10.0-month median duration of response, and disclosed FDA feedback supporting an NDA submission strategy for accelerated approval planned in Q1 2027. This is a material clinical and regulatory milestone for a precision oncology company's lead product candidate, but does not fit the specific event types (earnings, M&A, impairment, etc.); it is best classified as an operational milestone—the advancement of a key clinical program toward regulatory approval.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-08-31
The 6-K discloses that Ascendis Pharma has entered into a binding term sheet with BioMarin Pharmaceutical for a global settlement and license agreement related to the sale of YUVIWEL® and navepegritide-related products. The agreement resolves all litigation and disputes, grants Ascendis a non-exclusive worldwide royalty-bearing license to continue developing and commercializing navepegritide products, and establishes royalty payment obligations (20% in the US, 18% in EU/South Korea/Brazil through May 2030). This constitutes a material transaction involving intellectual property rights, product commercialization rights, and settlement of disputes that would materially affect investor assessment of the company's product portfolio and financial obligations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-31
Item 5.02
The filing discloses the appointment of Brian J. Comstock as Chief Executive Officer and President of Greenbrier, effective January 6, 2027, following the Board's succession planning process. While the section also mentions Lorie Tekorius's retirement, the principal action disclosed is Comstock's appointment to the CEO role, which is the forward-looking material event. The filing emphasizes the Board's deliberate succession process and Comstock's qualifications and experience, making the appointment the salient event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 3.02
Warburg Pincus Access Fund sold unregistered limited partnership units totaling $15.4 million to third-party investors on August 3, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions, representing a significant capital raise and expansion of the Fund's investor base.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-08-31
Item 1.01
OfferPad Solutions Inc. entered into a First Amendment to its revolving loan agreement that increases the principal uncommitted borrowing capacity from $100 million to $150 million, expanding the company's available debt capacity by $50 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-31
Item 5.02
The Board appointed Kristopher R. Westbrooks as President and Chief Executive Officer and Board member effective January 1, 2027, succeeding Michael S. Williams who is retiring effective December 31, 2026. The filing discloses detailed compensation arrangements for Westbrooks in his new role.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-31
Item 5.02
The filing discloses amendment and restatement of the Americold Logistics, LLC Executive Severance Benefits Plan, which increases severance multiples for Executive Vice Presidents and Presidents from 1.5x to 2.0x base salary plus bonus, and extends COBRA coverage from 18 to 30 months for the CEO and 12 to 24 months for EVPs/Presidents during Change in Control periods. This is a material modification to compensatory arrangements for named executives, fitting the exec_compensation category under Item 5.02(e).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-31
Item 7.01
The filing discloses a declared monthly distribution to shareholders of BlackRock Monticello Debt Real Estate Investment Trust across three classes of common shares (Class F-S, F-I, and E), with specific per-share amounts ($0.1927 gross, varying net amounts after servicing fees) payable on September 21, 2026. This is a routine but material dividend distribution typical of REITs, which are required to distribute substantially all taxable income to shareholders.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 5.02
The disclosure centers on the appointment of Tommy E. Darby as Vice President, Chief Accounting Officer of Westlake Corporation, effective immediately on August 31, 2026. While the filing also includes compensatory details (salary of $440,000, bonus targets, and a $135,000 sign-on RSU award), the principal action is the appointment of a named executive officer to a key financial leadership role. The transition of Jeffrey A. Holy to a different position is secondary to Darby's appointment. This is material as it involves a change in the chief accounting officer position, a critical role for financial reporting and internal controls.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 5.02
Tommy E. Darby was appointed to the position of Vice President, Chief Accounting Officer of Westlake Chemical Partners GP LLC (the general partner) effective immediately on August 31, 2026, and concurrently to the same role at Westlake Corporation. This is a material executive appointment to a senior financial officer position responsible for accounting oversight. While Jeffrey A. Holy's transition to a different role is also mentioned, the principal disclosed action centers on Darby's appointment to the Chief Accounting Officer position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-08-31
Item 1.01
ONEOK entered into a definitive agreement to acquire Brazos Midstream's Permian Midland Basin assets for $4.425 billion, funded by a $9 billion minority equity investment from Apollo Global Management and $5 billion of debt extinguishment. The transaction includes a holding company reorganization and concurrent debt tender offers, materially expanding ONEOK's Permian Basin platform and restructuring its capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-31
Item 3.02
ONEOK issued $9 billion of Class A and Class B Units in ONEOK Holdings, L.L.C. to Apollo funds in an unregistered private placement under Section 4(a)(2) of the Securities Act, representing a substantial minority equity investment that funds the Brazos acquisition and debt reduction.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-31
Item 8.01
Vylor Inc. issued $1.1 billion in aggregate principal amount of senior notes ($550 million due 2031 at 5.125% and $550 million due 2036 at 5.625%) in a private offering in connection with the Corteva separation. This is a material creation of direct financial obligations by a subsidiary that will be spun off as an independent public company, disclosed under Item 8.01 as part of the separation transaction structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 45%
filed 2026-08-31
Item 2.03
Kyntra Bio amended and restated its Revenue Interest Financing Agreement with NQ Project Phoebus, L.P., reducing maximum aggregate payments from $125 million to $65 million through a $42.6 million accelerated upfront payment. Combined with the FibroGen Europe bankruptcy settlement, the company reduced future liabilities by approximately $80 million, materially strengthening its balance sheet and extending cash runway into Q4 2027.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-31
Item 5.02
Kohl's appointed Ryan M. Waymire as Chief Merchandising Officer effective September 28, 2026, reporting directly to CEO Michael J. Bender. Waymire brings 25 years of retail leadership experience from Walmart, Amazon, Target, and other major retailers. The appointment was announced via press release and represents a significant governance event affecting leadership continuity and strategic direction.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-31
Item 1.01
Jazz Pharmaceuticals completed a $1.25 billion private offering of 1.875% exchangeable senior notes due 2032 through its subsidiary Jazz Investments I Limited on August 31, 2026. The senior unsecured notes are fully guaranteed by the parent company and represent a material creation of direct financial obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 3.02
Jazz Pharmaceuticals' exchangeable senior notes offering includes provisions for unregistered issuance of up to 5,014,125 ordinary shares upon exchange, with an initial exchange rate of 4.0113 shares per $1,000 principal amount (later priced at 2.8150 shares per $1,000), creating material potential equity dilution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-31
Item 1.01
Americold closed a material joint venture transaction with EQT's Active Core Infrastructure fund on August 31, 2026, contributing 12 cold storage facilities valued at over $1.3 billion to a newly formed partnership (Americold-EQT Cold Storage Partnership, LLC) in which EQT acquired a 70% interest and Americold retained 30%, while receiving approximately $1.1 billion in net cash proceeds and assuming the role of platform manager.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 3.02
The Fund completed unregistered sales of limited partnership units totaling approximately $10.0 million across two tranches (July 1 and August 3, 2026) to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D, diluting existing unitholders' ownership interests.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-08-31
Item 1.01
JATT III Acquisition Corp, a blank-check SPAC, consummated its IPO on August 27, 2026, raising $69 million in gross proceeds and entering into multiple material definitive agreements including an underwriting agreement, investment management trust agreement, registration rights agreement, and private placement shares purchase agreement with the sponsor.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 3.02
The Sponsor purchased 234,000 Ordinary Shares at $10.00 per share for $2.34 million in a private placement concurrent with the IPO, with transfer restrictions and registration rights typical of SPAC sponsor investments.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 5.02
On August 25, 2026, four independent directors—Verender S. Badial, Christopher Staral, Dr. Arjun Goyal, and Dr. Jonathon Kluft—were appointed to the Board and simultaneously appointed to chair or serve on the Audit, Compensation, and Nominating and Corporate Governance Committees in connection with the IPO.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-08-31
Item 8.01
JATT III Acquisition Corp completed a $69 million IPO on August 27, 2026, with proceeds placed in a trust account, establishing the capital base for the SPAC's stated purpose of pursuing a business combination in healthcare/biotech.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 94%
filed 2026-08-31
EX-99.2
Kazia announced a registered public offering of 2,580,000 ADSs (representing 1.29 billion ordinary shares) plus Series A and Series B Warrants, with expected gross proceeds of approximately $40 million before underwriting costs and potential additional proceeds of ~$80 million if warrants are exercised. The offering is tranched and involves dilutive equity issuance to raise capital for clinical development.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 5.02
Morris Berger was appointed as Chief Executive Officer effective October 1, 2026, with Jonathan Reich transitioning from CEO to President and Chief Operating Officer. The appointment includes a $450,000 base salary, $50,000 signing bonus, and equity options equal to 3% of outstanding shares, supported by a $7.5 million insider investment by Berger.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-31
Item 7.01
Zedge announced a proposed private placement of Class B common stock and warrants to accredited investors for approximately $7.5 million, led by Vice Chairman Howard Jonas, with 90% warrant coverage at 110% exercise price, to accelerate DataSeeds growth.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-31
Item 5.02
Stephan Gratziani's transition from Chief Executive Officer effective October 31, 2026 constitutes an executive departure. The CEO is a named executive officer whose departure materially affects investor assessment of the registrant's leadership and continuity. The filing discloses the departure date but does not indicate a successor appointment in this section, making the departure the principal disclosed action.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-31
EX-99.1
The press release announces the resignation of Mr. Nan Hu as a director of Nano Labs Ltd, effective August 31, 2026. This is a clear executive departure event. While the Company states the resignation is not expected to affect operations, director departures are material governance events that affect the composition of the board and oversight structure, warranting disclosure to investors.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-31
Mr. Yiu Wai Ming resigned from his position as an independent director effective August 31, 2026, and also stepped down from his roles as chair of the compensation committee and member of the audit and nominating committees. This is a clear executive departure involving loss of board leadership and committee chair responsibilities. The resignation is material because it affects board composition and governance structure, though the company confirms no disagreement or dispute was involved.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
This press release announces completion of patient enrollment in the IMPACT clinical trial for Alpha DaRT in pancreatic cancer, with enrollment expanded three times from 12 to 48 patients. The disclosure highlights a significant operational and clinical milestone — successful rapid enrollment in a pivotal pilot study that will inform design of a planned pivotal trial — which is material to investors assessing the company's clinical development progress and commercial prospects for its lead therapeutic candidate. The event does not fit a discrete named category (not an earnings release, M&A activity, executive change, or other specific event type), but is clearly a material operational/clinical development milestone.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-31
The 6-K discloses an amendment to securities purchase agreements dated August 26, 2026, relating to the issuance of Class A ordinary shares to investors at a significant discount (20% of closing price). The Company previously issued 4,310,350 shares on July 8, 2026 and 6,329,115 shares on August 11, 2026, totaling over 10.6 million shares for $2 million in aggregate proceeds. This represents a dilutive private placement of unregistered equity securities, a material capital-raising event typical of small-cap issuers under financial pressure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-31
Item 8.01
Cadrenal announced positive feedback from an FDA Type D meeting on July 28, 2026, regarding alignment on the primary endpoint definition and Statistical Analysis Plan for the Phase 3 registrational study of CAD-1005 for heparin-induced thrombocytopenia. FDA agreement on trial design elements represents a material regulatory milestone that advances the company's path to potential commercialization of this first-in-class therapeutic.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
The filing discloses completion of Phase 2 development of the Company's Catch-Up agentic AI video platform in collaboration with AWS and Caylent, with AWS providing $125,000 in project funding. This is a material operational milestone—the successful completion of a contingent development project with a strategic partner and receipt of associated funding—but does not fit neatly into specific categories like debt issuance, M&A, or earnings release. It is clearly operational/strategic in nature and material to investors evaluating the Company's product development progress and AI strategy.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-31
Item 3.01
Profusa received a Determination Letter from Nasdaq on August 26, 2026, notifying the Company that following its 1-for-4 reverse stock split, it had fewer than the 500,000 publicly held shares required under Nasdaq Listing Rule 5550(a)(4). Although Nasdaq subsequently determined compliance as of August 21, 2026, the filing itself discloses receipt of a deficiency notification under Item 3.01 and explicitly states this is filed to comply with Nasdaq Listing Rule 5810(b) requiring prompt disclosure of such notices. This is a material delisting-risk disclosure even though the immediate compliance issue was resolved.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
EX-99.1
Turbogen announced approval and commencement of trading of its ordinary shares on the Nasdaq Capital Market on August 31, 2026, while maintaining its existing listing on the Tel Aviv Stock Exchange. This is a material operational and strategic milestone — a secondary listing on a major U.S. exchange — that expands the company's capital market access and investor base. While not a discrete M&A event, debt issuance, or governance action, it is a significant operational/strategic development that would affect a reasonable investor's assessment of the company's profile, liquidity, and growth prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-31
Item 8.01
The filing discloses a material update to an ongoing business combination between IPEX and GOWell Technology Limited. The core disclosure is an extension of the redemption deadline from September 1, 2026 to September 2, 2026, and notification that shareholders may withdraw previously submitted redemption requests. This is a procedural update to a previously announced material acquisition/merger transaction that would result in a change of control and creation of PubCo as the combined entity. The Business Combination Agreement was entered into on October 13, 2025, and amended twice, with the Registration Statement declared effective on August 11, 2026, indicating the transaction is in advanced stages toward consummation.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-08-31
The 6-K discloses the results of a Special General Meeting of Shareholders held on August 31, 2026, where a proposal was voted upon and approved by the requisite majority of shareholders. While the specific proposal details are referenced in an earlier proxy statement (Exhibit 99.1 from August 17, 2026), this filing reports the voting outcome itself, which is the hallmark of shareholder_vote_results. The materiality is presumed because special shareholder meetings typically address significant corporate matters (governance, M&A, capital structure, etc.), and approval by shareholders is material to investors' assessment of the company's direction.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-08-31
EX-99.1
CollPlant has signed a definitive agreement to acquire LightSolver Ltd., an Israeli deep-tech company, with closing expected imminently. The transaction involves material equity consideration (3.7M upfront shares representing 19.7% of CollPlant's outstanding capital, plus pre-funded and milestone-based warrants for up to 224M additional shares), representing a significant change of control and strategic expansion into photonic computing markets. This is a classic material acquisition disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 1.01
Tenon Medical completed a $3.0 million private placement on August 31, 2026, issuing 597,610 shares of common stock (or pre-funded warrants) and warrants to purchase 1,058,517 additional shares under Section 4(a)(2) and Regulation D exemptions. The company intends to use proceeds for debt repayment and working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-31
Item 3.02
Zoomcar completed a warrant exchange offer, issuing approximately 317.7 million shares of common stock in exchange for 6.03 million existing warrants (approximately 63% of outstanding warrants). The shares were issued as restricted securities under Section 3(a)(9) exemption with no cash consideration, materially affecting the company's capital structure and warrant overhang.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-31
Item 3.03
Change Agents Corporation implemented a 1-for-20 reverse stock split effective August 28, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. The reverse split, approved by stockholders on June 9, 2026, and effectuated via Charter Amendment, directly addresses the company's delisting risk stemming from its stock price falling below the Nasdaq listing threshold.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-31
The filing discloses entry into multiple letter agreements creating direct financial obligations: two advances of $0.03 million each from Hazel Partners Holdings LLC under an existing working capital credit facility (funded August 18 and August 28, 2026), and two advances of $0.03 million each from VRM MSP Recovery Partners, LLC (funded August 14 and August 28, 2026). Item 1.01 and Item 2.03 explicitly address creation of direct financial obligations. While the amounts are modest, the disclosure emphasizes the discretionary nature of the facility and the company's precarious liquidity position—notably that "no remaining funding capacity was available" under the Operational Collection Floor as of Q3-2025, and that these are "standalone accommodations" with no commitment for future funding, suggesting material financial stress.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 5.08
The material event disclosed is the appointment of independent director Lee McIntire as Chief Executive Officer, effective August 11, 2026. While the Item 5.08 section addresses routine shareholder meeting logistics and nomination deadlines, the substantive disclosure in Item 8.01 (Other Events) centers on McIntire's appointment to the CEO role—a senior executive appointment that would materially affect investor assessment of the company's leadership. The associated Audit Committee changes (McIntire's resignation and Stein's appointment) are secondary governance adjustments flowing from the CEO appointment.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-31
The 6-K discloses entry into an At-The-Market (ATM) sales agreement on August 31, 2026, permitting the Company to offer and sell up to $50,000,000 of Class A ordinary shares through Craft Capital Management LLC. This is a dilutive equity issuance arrangement that would materially affect existing shareholders' ownership and is a strong signal of capital-raising activity typical of small- and mid-cap issuers.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-08-31
This 6-K discloses the Company's adoption of a dual-class share capital structure (Class A with 1 vote per share, Class B with 50 votes per share) and its election to follow Cayman Islands corporate governance rules in lieu of certain Nasdaq rules (annual meeting timing, voting rights protections, and shareholder approval thresholds). The dual-class structure materially affects voting power and control, approved at the July 10, 2026 annual general meeting. This is a governance event that would affect a reasonable investor's assessment of voting rights and control dynamics.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-31
Item 1.01
On August 27, 2026, the Company completed a secured financing transaction with SRX Global Inc., issuing a Consolidated Senior Secured Promissory Note that consolidates $5.67 million in previously outstanding convertible promissory notes and provides for up to $6 million in additional advances, for a maximum aggregate loan amount of $11.67 million. The Note is secured by a first-priority security interest in substantially all of the Subsidiary's assets, including intellectual property and clinical trial assets related to the Company's CER-T cell therapy business.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 3.02
The Company issued an unregistered convertible promissory note under Section 4(a)(2) of the Securities Act to an accredited investor, with shares of common stock issuable upon conversion, creating potential equity dilution.
View raw filing on EDGAR →
8-K
Going Concern
confidence 85%
filed 2026-08-31
Item 8.01
The filing discloses the Company's active assessment of liquidity-improvement plans and engagement of a financial advisor to evaluate "strategic financing alternatives and balance sheet management initiatives." Most critically, the forward-looking statements section explicitly references "the risks associated with our expression of substantial doubt about our ability to continue as a going concern," which is the unmistakable language of going-concern disclosure. The Company's decision to rely on 30-day grace periods for interest payments on Senior Unsecured Notes due 2027 and 2028, while stating it has sufficient cash, signals financial stress and the need for a capital solution from majority equity holders.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-31
The 6-K discloses the results of Kornit Digital's 2026 annual general meeting of shareholders held on August 31, 2026, with detailed vote tallies on three proposals: (1) re-election and initial election of directors (Naama Halevi Davidov, Gabi Seligsohn, and Nick Beighton); (2) adoption of a renewed compensation policy for office holders; and (3) re-appointment of the independent auditor Kost Forer Gabbay & Kasierer. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, reporting the outcomes of all proposals voted upon at the annual meeting with specific vote counts and percentages.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-31
Item 5.02
The filing discloses both the departure of CEO Katharyn Field and the appointment of Shahin Behroyan as Chief Executive Officer, effective August 26, 2026. While both events occurred, the principal disclosed action centers on the appointment of a new CEO with detailed background, qualifications, and a new Independent Contractor Agreement ($350,000 annual fee). The appointment of a new chief executive is material to investors and represents the salient event, though the departure is also disclosed.
View raw filing on EDGAR →